

11 July 2022

ASX ANNOUNCEMENT

Lymphoedema Risk Factors Paper Published

ImpediMed Limited (ASX:IPD) (**ImpediMed**) is pleased to announce the publication of a paper on the risk factors for breast cancer related lymphoedema. The paper was published in *Cancer*, an international, interdisciplinary journal of the American Cancer Society, which publishes high-impact, peer-reviewed original articles and solicited content on the latest clinical research findings.

Key findings included:

- The publication supports the use of a prospective surveillance model of care and **identifies patients who may benefit from more frequent follow-up.**
- The paper supported previous studies in identifying patients at higher risk to progress to clinical breast cancer-related lymphoedema (BCRL). These included patients receiving axillary lymph node dissection (ALND), taxane-based chemotherapy, regional nodal irradiation (RNI), or those with a body mass index >30.
- Additionally, the authors found that residing in a rural location increased risk, whereas air travel did not increase risk.

The journal also commissioned an editorial which has been published in conjunction with the manuscript.

Salient points included:

- The authors are completely independent and represent some very prestigious institutions, including Harvard Medical School, Dana-Farber Brigham Cancer Center and University of Rochester Medical Center.
- They commented that the work “contributes greatly to the body of BCRL literature because it describes individual patient risk factors for BCRL development in an international, prospective cohort”.

“All individuals at risk of lymphoedema following breast cancer should have access to a prospective surveillance and early intervention (PSEI) model of care. Risk factors for BCRL have been previously established outside of the PSEI model, and this study supports these findings within the context of the PSEI model. This study highlights those individuals at higher risk such as those who have undergone ALND, taxane and RNI may require closer follow-up than current routine follow-up intervals,” stated first author Louise Koelmeyer PhD, BAppSc (OT) - Director & Senior Lecturer | ALERT Program – Australian Lymphoedema Education, Research & Treatment.

“This study represents the most comprehensive, prospective examination of breast cancer related lymphoedema risk factors to date. The findings will not only inform clinical practice and patient education, but may also relieve some of the distress regarding air travel frequently voiced by breast cancer survivors,” added Principal Investigator Sheila H. Ridner, PhD, RN, FAAN, research professor at Vanderbilt University School of Nursing.

"Randomised trials the size of the PREVENT Trial are the highest level of scientific evidence. The data gathered from the PREVENT Trial and the continued work of the investigators leading this study will help us expand access to L-Dex testing for millions of patients worldwide," stated Richard Carreon, Managing Director and CEO of ImpediMed.

A link to the manuscript and editorial can be found here:

Link to manuscript:

<https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34377>

Link to editorial:

<https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34374>

Approved for release by the Managing Director and CEO, Mr. Richard Carreon.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.